Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...

The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress ...

Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free ...

The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...

SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...

BioInvent International AB ($BOVNF) announced an update on their ongoing clinical study. Study Overview: BioInvent International AB, in ...

Lytix Biopharma AS ($DE:6BG) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 2 Study of ...

Early MRI predicts pathologic complete response and long-term outcomes in TNBC patients receiving pembrolizumab.

Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple ...

Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...